Comparative Pharmacology
Head-to-head clinical analysis: LANTRISUL versus NEOBIOTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANTRISUL versus NEOBIOTIC.
LANTRISUL vs NEOBIOTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lantrisul (sulfadimethoxine) is a sulfonamide antibiotic that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for the enzyme dihydropteroate synthase, thereby blocking folic acid synthesis and ultimately nucleic acid production in susceptible bacteria.
NEOBIOTIC is a combination antibiotic product containing neomycin (aminoglycoside) and bacitracin (polypeptide antibiotic). Neomycin binds to the 30S ribosomal subunit of bacteria, causing misreading of mRNA and inhibiting protein synthesis. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan subunits.
Intravenous: 3 mg/kg every 8 hours for 14 days, then 5 mg/kg every 12 hours for 14 days; oral: 800 mg (10 mg/kg) twice daily after intravenous phase.
1 g intravenously every 12 hours.
None Documented
None Documented
Terminal elimination half-life is 18 hours (range 16-20 h). This supports once-daily dosing; steady-state achieved after 3-4 days.
3.5–4.5 hours (terminal) in adults with normal renal function; prolonged to 12–18 hours in severe renal impairment (CrCl <30 mL/min).
Approximately 70% renal excretion as unchanged drug, 15% fecal elimination via biliary secretion, 10% metabolized to inactive glucuronide conjugate eliminated renally, 5% other minor pathways.
Renal: 30–40% unchanged; fecal: 50–60% via biliary elimination; minimal hepatic metabolism.
Category C
Category C
Antibiotic
Antibiotic